background: The aim of this study was to ascertain the prevalence of meiotic segregation products in embryos from carriers of 13/14 and 14/21 Robertsonian translocations and to estimate the predictive value of testing single cells using the fluorescence in situ hybridization (FISH) technique, to provide more information for decision-making about PGD.
Introduction
Robertsonian translocations are found in 1 in 1000 births, and the most common translocations are between chromosomes 13 and 14 and between chromosomes 14 and 21 (Gardner and Sutherland, 2004) . Trivalent formation of non-homologous chromosomes at meiosis I allows synapsis of the homologous chromosomes, and segregation produces eight different products in gametes: normal chromosomes or the Robertsonian translocation chromosome (alternate segregation), four products with nullisomy or disomy for one chromosome (adjacent segregation) and two products with nullisomy or disomy for both chromosomes (3:0 segregation) (Gardner and Sutherland, 2004) . Alternate segregation is favoured for male and female carriers; however, female carriers are more likely to produce unbalanced gametes than male carriers (Munné et al., 2000a) . There is a 10-fold excess of Robertsonian translocations found in males with oligozoospermia (Chandley, 1988) , for whom assisted conception with ICSI is likely to be indicated.
Conceptions with trisomy for chromosome 13 or 21 can result in offspring with Patau and Down syndrome, respectively. Other unbalanced products are not compatible with life and might fail to implant, or result in occult pregnancy or first-trimester miscarriage. The risk of miscarriage is increased for some carriers compared with the general population background risk of 15%. Trisomy rescue (or more rarely monosomy rescue) can result in an apparently balanced (or normal) karyotype with uniparental disomy (UPD). Prenatal diagnosis (PND) is possible, at which the empirical risk of trisomy 21 or UPD 14 is 15% for a female carrier and 1% for a male carrier of a 14/21 translocation, while the risk of trisomy 13 or UPD 14 for female and male carriers of a 13/14 Robertsonian translocation is 1% (Gardner and Sutherland, 2004) . PGD offers another reproductive option for some couples. However, PGD should only be embarked upon following careful genetic counselling (taking into account the previous obstetric history of the couple and other carriers in the family), calculation and discussion of appropriate risk figures, and investigations for recurrent miscarriage when indicated (Scriven et al., 2001) .
Successful treatment for carriers of Robertsonian translocations using PGD and assisted reproduction technology has been applied clinically for more than a decade using polar body biopsy (Munné et al., 1998a (Munné et al., , 2000a and blastomere biopsy (Escudero et al., 2000; Munné et al., 2000b) . Fluorescence in situ hybridization (FISH) has been the primary technique used to test preimplantation oocytes and embryos. In the largest multi-centre data collection, the clinical pregnancy rate for PGD cycles reported to the ESHRE PGD Consortium to the end of 2007 was 23% (268/1146 biopsy cycles; Harper et al., 2010) . The largest series from a single centre published to date achieved a live birth delivery rate of 33% (24/76 couples) for couples who had at least one cycle of PGD and it was concluded that PGD is a good reproductive option, especially when there is also a fertility problem (Keymolen et al., 2009) .
The reproductive risks for carriers of 13/14 and 14/21 translocations at PND are well established but less well studied at conception for female carriers. Our study presents 10 years of experience of PGD for carriers of 13/14 and 14/21 Robertsonian translocations at the Guy's and St Thomas' Centre for PGD. We have investigated the prevalence of meiotic segregation products seen in cleavage-stage embryos from male and female carriers and evaluated the diagnostic accuracy of testing using the FISH technique and the success of the treatment.
Materials and Methods

Patients
Our prospective cohort study included 28 consecutive couples undergoing PGD at the Guy's and St Thomas' Centre for PGD between February 1999 and May 2008; none of the couples treated had a successful pregnancy before PGD. There were seven female carriers of 13/14 Robertsonian translocations [45, XX, der(13; 14)(q10; q10) ], four with a history of recurrent miscarriage and three with infertility, and eleven male 13/14 carriers [45,XY,der(13;14)(q10;q10)], nine with infertility and two with partners with a history of recurrent miscarriage. There were also five females carriers of 14/21 Robertsonian translocations [45, XX, der(14; 21 ) (q10;q10)]-two with a family history of translocation trisomy 21, one with a pregnancy termination for trisomy 21, one with a partner with male factor infertility and one with a history of recurrent miscarriage-and five male 14/21 carriers [45,XY,der(14;21)(q10;q10)]-four with infertility and one with a partner with a history of recurrent miscarriage.
Ovarian stimulation, embryo culture and biopsy, and confirmation of diagnosis Procedures were performed as described previously (Khalaf et al., 2000; Scriven et al., 2000; Pickering et al., 2003) . In brief, a standard long stimulation protocol for controlled ovarian stimulation was followed by IVF, or ICSI when the patient had suboptimal semen characteristics, then biopsy of one or two cells from cleavage-stage embryos 3 days after fertilization and embryo transfer on Day 4 or 5. Two testing strategies were used over the period of the study. The first strategy included biopsying one cell from embryos with five or more cells on Day 3 and a second cell if the first cell did not have a clear single nucleus after lysis and the embryo had six or more cells; in the event of 1-cell being mononucleated and the second cell being multinucleated, only the mononculeated cell was analysed for diagnosis. The second strategy included biopsying two cells from embryos with six or more cells on Day 3; embryos diagnosed to be normal/balanced had a concordant result from both cells tested. Embryos unsuitable for freezing were spread for confirmation of diagnosis (COD) and further analysis with FISH in accordance with Human Fertilization and Embryology Authority research licence R0075. Where embryos had been transferred, G-band karyotyping at PND or of live born offspring was carried out when possible.
Fluorescence in situ hybridization FISH probe selection, blastomere spreading, in situ hybridization and signal scoring protocols have been described in detail previously (Scriven et al., 2001; Scriven and Ogilvie, 2007) . In general, the risk of misdiagnosis was minimized either by using two diagnostic probes for each viable imbalance (26 cycles), or by testing two cells and transferring embryos with concordant normal/balanced results from both cells (4 cycles).
Probe mixes and strategies used for der(13;14) cycles were:
(1 Blastomeres and whole embryos were spread using the Tween/HCl method (Coonen et al., 1994) . Prepared nuclei were hybridized overnight and analysed using a fluorescence microscope suitably equipped with the appropriate filter sets for the probes being used.
COD and assigning the mode of segregation
Normal test results and spread embryos were assigned to be consistent with alternate segregation at meiosis if the nuclei(us) showed two signals for each chromosome region tested, for the single nucleus from a transferred embryo where COD was not possible or at least two nuclei from spread embryos. For the diagnostic accuracy study, spread embryos were confirmed to be normal/balanced if at least 50% of nuclei were consistent with normal copy number. Abnormal tests results were deviations from a normal test result and spread embryos were confirmed to be abnormal if .50% of nuclei were abnormal, and assigned to be consistent with adjacent or 3:0 segregation at meiosis if at least two nuclei obtained showed the appropriate and consistent deviation from two signals for each chromosome region tested. Haploid and triploid results were differentiated from 3:0 segregation products by retesting with a probe specific for a chromosome not involved in the translocation. The likely segregation mode was deemed to be unknown if these criteria were not met.
Statistical analysis
The odds ratio (OR) of unbalanced translocation segregation products for female and male heterozygotes was calculated using logistic regression, controlling for the type of translocation, age of the female partner and fertility status. Test results with an unknown outcome were initially allocated in proportion to normal and abnormal test results with a known outcome; in a sensitivity analysis, we varied the allocation of normal test results up to the upper 95% confidence limit of zero.
Of the two types of potential error, a false-negative result (which could lead to implantation failure, miscarriage or the birth of a chromosomally abnormal child) has implications different from a false-positive result, which could involve a chromosomally balanced embryo not being selected for replacement. The primary diagnostic accuracy measures calculated were the positive predictive value (the probability that an abnormal test result is correct) and the negative predictive value (the probability that a normal test result is correct). Other statistics calculated were: proportion of false positives and false negatives (using the test perspective and calculated as the proportion of the total outcomes), overall accuracy (the proportion of all test results that are correct), sensitivity (the probability that a non-transferable genotype has an abnormal test result) and specificity (the probability that a transferable genotype has a normal test result). The primary outcome measure was the live birth rate per couple; the live birth rate per biopsy cycle was also calculated. For study measures, 95% confidence intervals (CIs) were calculated and Pearson's goodness of fit x 2 was calculated for significance probabilities. Log-likelihood ratios were used to test for patient heterogeneity within the segregation analysis patient groups.
Results
Our study included a total of 311 embryos tested from 42 cycles for 18 carriers of 13/14 and 10 carriers of 14/21 Robertsonian translocations. For 12 female carriers (Table I) , there were 7 (58%) healthy live born deliveries. A total of 129 embryos were tested: 57 (44%) had a normal test result, 67 (52%) had an abnormal test result and 5 (4%) failed to be diagnosed. Following COD, 23/23 (100%) embryos diagnosed to be normal were confirmed as normal and none was found to be abnormal; 34 embryos for which a result could not be obtained were therefore assigned as normal. For the embryos diagnosed to be abnormal, 46/58 (79%) were confirmed to be abnormal and 12 were found to be normal; results were not obtained for nine embryos and seven were therefore assigned as abnormal and two as normal. Table III summarizes the proportion of abnormal cells found in 58 reanalysed embryos; 21 embryos were mosaic and 15 (71%) had only abnormal cells. Table IV shows the diagnostic accuracy measures: the prevalence of abnormal embryos was estimated to be 43% and it was estimated that the test had 89% accuracy, 100% sensitivity, 80% specificity, 79% positive predictive value and 100% negative predictive value. Following the sensitivity analysis to adjust for potential undetected abnormal embryos (see statistical analysis section above), the prevalence changed to 46% and the sensitivity and negative predictive value to 93 and 93%, respectively.
For 16 male carriers (Table II) , there were eight deliveries (50%). A total of 182 embryos were tested, of which 91 (50%) had a normal test result, 90 (49%) had an abnormal test result and 1 (,1%) failed to be diagnosed. Following COD, 36/36 (100%) embryos diagnosed to be normal were confirmed and none was found to be abnormal; 55 embryos for which a result could not be obtained were therefore assigned as normal. For the embryos diagnosed to be abnormal, 41/73 (56%) embryos were confirmed to be abnormal and 32 were found to be normal; a result was not obtained for 17 embryos and 10 were therefore assigned as abnormal and 7 as normal. Table III summarizes the proportion of abnormal cells found in 73 reanalysed embryos; 36 embryos were mosaic and 23 (64%) had only abnormal cells. The prevalence was estimated to be 28% (Table IV) and it was estimated that the test had 78% accuracy, 100% sensitivity, 70% specificity, 57% positive predictive value and 100% negative predictive value. Following the sensitivity analysis, the prevalence changed to 30% and the sensitivity and negative predictive value to 93 and 96%, respectively.
Excluding one couple who had a termination of pregnancy at 14 weeks gestation for social reasons, 7/10 (70%, 95% CI 35-93%) fertile Robertsonian couples who had at least one biopsy cycle had a healthy live birth pregnancy, 3/10 (30%, 95% CI 7 -65%) had a 'biochemical' pregnancy and 1/8 (13%, 95% CI ,1-53%) a failed pregnancy after the detection of a foetal heartbeat.
Our segregation analysis included 257 embryos. Tables I and II show that 40/58 (69%) embryos from female 13/14 carriers were consistent with alternate segregation as were 76/91 (84%) embryos from male carriers (difference 21%, 95% CI 10 -47%, P ¼ 0.037). For the 14/21 translocation, 31/49 (63%) embryos from female carriers were consistent with alternate segregation as were 56/59 (95%) embryos from male carriers (difference 50%, 95% CI 20-87%, P , 0.001).
Controlling for the translocation type, embryos of female Robertsonian translocation carriers were approximately four times more likely to have an embryo with an unbalanced translocation product than were male carriers (OR 3.8, 95% CI 2.0 -7.2, P , 0.001). Age and fertility status did not confound the association between sex and segregation outcome and, controlling for sex, age and fertility status, were not important independent predictors of chromosome imbalance.
Trisomy 13 was found in 4/58 (7%) embryos of female 13/14 carriers and in 2/91 (2%) embryos of male carriers (difference 214%, P ¼ 0.155); trisomy 21 was found in 11/49 (22%) embryos of female 14/21 carriers and 0/59 (0%) embryos of male carriers (difference infinity %, P , 0.001).
Discussion
The objective of our study was to ascertain the prevalence and OR of unbalanced meiotic segregation products in cleavage-stage embryos from female and male carriers of 13/14 and 14/21 Robertsonian translocations and to estimate the predictive value of testing biopsied blastomeres using FISH, to provide better information for couples and professionals involved in decision-making about PGD.
Where the likely mode could be ascertained, the majority of embryos were consistent with alternate segregation (Tables I and  II) . Fewer embryos from female carriers (69%) were consistent with alternate segregation compared with embryos from male carriers (84%). Female translocation carriers were approximately four times more likely than male carriers to have embryos with an unbalanced product of the translocation (OR 3.8; 95% CI 2.0-7.2, P , 0.001). More embryos from female carriers had potentially viable translocation trisomy products than did embryos from male carriers: 7 and 2%, respectively, for trisomy 13, and 22 and 0%, respectively, for trisomy 21.
In contrast to a conventional accuracy study, which compares test results with a clinical reference standard, measuring the diagnostic accuracy of PGD in practice is complicated by the nature of the early human embryo and confounded by incomplete results (many embryos transferred fail to implant and might include some with false normal test results). Our primary testing strategy was to minimize the risk of transferring an embryo with viable chromosome imbalance by using two FISH probes for chromosomes 13 and 21, and therefore it is not unexpected that all the resulting offspring tested were confirmed to have a normal or balanced translocation chromosome complement, which inevitably biases the accuracy of our study. In practice, the most appropriate measure of diagnostic accuracy is likely to be the positive predictive value because all the abnormal test results have the possibility of being available for COD studies (Scriven and Bossuyt, 2010) . Our approach in this study was to allocate test results with an unknown outcome in proportion to normal and abnormal test results with a known outcome and then vary the allocation of normal test results in a sensitivity analysis. Table IV shows that the prevalence of chromosome imbalance for the chromosomes tested in embryos from female carriers was estimated to be 43%, the predictive value of an abnormal test result was 79% and the initial predictive value of a normal test result was 100%; following the sensitivity analysis, the negative predictive value was 93%. The prevalence of chromosome imbalance for the chromosomes tested in embryos from male carriers was estimated to be 28%, the predictive value of an abnormal test result was 57% and the initial predictive value of a normal test result was 100%; following the sensitivity analysis the negative predictive value was 96%. In addition to the limitations of the FISH technique, mosaicism has the potential to produce false abnormal and false normal test results; however, as observed in our Segregation of Robertsonian translocations study (Table III) and by others (Colls et al., 2007) , the majority of mosaic embryos have only abnormal cells and this is expected to mitigate the error rate associated with mosaicism (Munné et al., 2010) . For female carriers, the overall accuracy of our PGD testing using FISH was estimated to be 89%, which roughly equates to 96% per probe for three probes (0.89 1/3 ), and is broadly similar to the 80 -82% accuracy rates testing (mainly) five chromosome pairs ( 96% per probe) previously reported for aneuploidy screening using FISH (Munné et al., 1998b; Silber et al., 2003) . More recently, experienced groups have reported a much higher accuracy for 1-and 2-cell biopsy testing for six chromosome pairs (93 and 97% accuracy respectively; 99% per probe) (Michiels et al., 2006) and employing a 'no result rescue' technique testing eight chromosome pairs (95% accuracy, 99% per chromosome pair) (Colls et al., 2007) . When testing for chromosome rearrangements, our priority was to avoid transferring an embryo with an unbalanced translocation and our practice, especially when several embryos were available for transfer, was to err on the side of caution when interpreting closely adjacent 'split' signals and scoring normal copy number. It is therefore consistent, given the significantly lower prevalence of chromosome aneuploidy found in embryos from male carriers (28 versus 43%) that more normal embryos were excluded due to error (30 versus 20%), resulting in a lower overall test accuracy for male carriers (78 versus 89%) ( Table IV) . The proportion of embryos tested with a transferable test result was similar for female and male carriers (44 and 50%, respectively) (Tables I and II) .
Of our 16 male carriers, 13 presented with infertility. There is a 10-fold excess of Robertsonian heterozygotes in men with oligozoospermia (Chandley, 1988) . Studies in males with severe oligozoospermia have found a high proportion (.60%) of cells with non-random association between the sex vesicle and the Robertsonian trivalent for 13/14 and 14/21 translocations (Luciani et al., 1984; Rosenmann et al., 1985) . Associations tended to occur where there was pairing failure in the short arms of the two non-translocated chromosomes. Whether such non-random contacts are the cause of germ-cell breakdown or a secondary consequence of a primary pairing failure is not clear (Chandley, 1988) , but it is plausible that incomplete synapse will result in disproportionate death of cells with chromosome aneuploidy and explain, at least in part, the reduced level of aneuploidy in mature spermatozoa compared with fertilized oocytes. It is probable that Robertsonian translocations have a negative effect on sperm count for all male carriers and that oligoospermia or azoospermia is only a matter of degree.
In general, most sporadic chromosome aneuploidy originates during oogenesis (typically meiosis I) and increases with maternal age (Hassold and Hunt, 2001) . Altered recombination appears to be the most important known factor associated with the origin of human trisomy (Lamb et al., 2005) ; homologous chromosomes that fail to crossover are expected to produce random segregation at metaphase I and a 50% chance of non-disjunction. Other possible factors include the position of crossovers relative to the centromere and loss of sister chromatid cohesion or defects in spindle assembly or disassembly (Hassold et al., 2007) . It is therefore consistent that, compared with males, these mechanisms are likely to be contributing to the additional chromosome aneuploidy in embryos from female Robertsonian heterozygotes. Table V incorporates our study and previous studies of 13/14 and 14/21 Robertsonian translocations that have investigated segregation products in spermatozoa, polar bodies and oocytes, embryos and pregnancies. In general, the proportion of products consistent with alternate segregation is similar in gametes and preimplantation embryos and is greater for male carriers (85-95%) than female carriers (57 -67%). Conceptions with whole chromosome imbalance, particularly monosomy, are more likely to fail than those with a normal or balanced chromosome complement, and the proportion of pregnancies with an unbalanced translocation at PND is therefore expected to be reduced; the remaining risk is associated with translocation trisomy for chromosomes 13 or 21 (1% for male carriers of both translocations and female 13/14 carriers, and 15% for female 14/21 carriers). Expressing the number of embryos with trisomy 13 or 21 as a proportion of the embryos with trisomy 13 or 21 plus those with a normal/balanced chromosome complement (the total products with potential to survive to PND), for female and male carriers, respectively, 11% (95% CI 4-23%) and 3% (95% CI 1 -8%) had trisomy 13, and 26% (95% CI 14 -42%) and 0% (95% CI 0-6%) had trisomy 21. The much lower prevalence of these abnormalities at PND (Table V) demonstrates a substantial degree of embryo loss between conception and prenatal diagnosis. A significant rate of foetal death is also expected for trisomy 13 and 21 (Hook, 1978 (Hook, , 1980 and it is logical to conclude that the risk of miscarriage for Robertsonian heterozygotes might be increased compared with the general population risk of 15%. The 13/14 Robertsonian study of Harris et al. (1979) included 86 sibships and found that 16% (95% CI 11-22%) of pregnancies ended in miscarriage for female carriers compared with 9% for male carriers. A criticism of this study is that exclusion of all miscarriages with an unknown karyotype might have over-corrected for ascertainment bias (Engels et al., 2008) . The ascertainment-corrected study of Engels et al. (2008) which included 101 pedigrees of carriers of 13/14 Robertsonian translocations, found that 28% (95% CI 20 -36%) of pregnancies for female carriers and 20% (95% CI 11 -31%) for male carriers resulted in miscarriage.
Evidence from studies of gametes, embryos and pregnancies indicates that the risk of a translocation trisomy 21 conception and pregnancy is significant for a female 14/21 heterozygote; PGD can therefore be considered a realistic alternative to PND for fertile as well as infertile couples, in order to avoid Down syndrome (Fig. 1 summarizes the decision pathway for PGD). The risk of an unbalanced translocation for a male 13/14 or 14/21 heterozygote is low and PGD for fertile couples is therefore unlikely to be indicated; our study indicates that even for infertile couples (accepting that the test will have some utility in detecting triploid and chromosomally chaotic embryos), the predictive value of an abnormal test result using the FISH technique is relatively low and embryo transfer without PGD (and additional cost) should be considered a reasonable choice, especially where few embryos are available for testing. Male and female 13/14 heterozygotes have a low risk of translocation trisomy 13 at PND; however, our study indicates that female carriers are more likely to produce aneuploid embryos than male carriers, and, in conjunction with recent evidence showing that female carriers have an increased risk of miscarriage compared with the general population background risk (Engels et al., 2008) , PGD should be considered as a reproductive option for carrier females in fertile couples with a history of recurrent miscarriages. However, other contributing factors should also be investigated and we recommend a uterine cavity assessment and testing for antiphospholipid syndrome and Lupus anticoagulant. It is our opinion that PGD for fertile male carriers of 13/14 Robertsonian is unlikely to be indicated. It is worth noting that in an index-control study of carriers of Robertsonian translocations with a history of two or more miscarriages, in a 2 year follow-up period there was no significant difference in subsequent pregnancy outcome between these carriers and couples with normal karyotypes; 82 and 84% of couples had one or more healthy children while 34 and 30% had one or more miscarriage, respectively (Franssen et al., 2006) . Our experience with PGD for fertile Robertsonian couples is that 70% had a healthy live birth pregnancy and 30% had a failed pregnancy.
In their study of 76 couples with Robertsonian translocations, Keymolen et al. (2009) concluded that, based on a live birth rate of 33% per couple, PGD is a good reproductive option for such couples, especially when there is also a fertility problem; however, that study did not examine the predictive accuracy of the testing, nor did it present the prevalence of abnormal findings in the different groups represented in their study.
For more than a decade, FISH on the fixed nuclei of biopsied cells with target-specific DNA probes has been the technique of choice to detect chromosome imbalance associated with chromosome rearrangements (Conn et al., 1998; Munné et al., 1998a; Pierce et al., 1998; Harper et al., 2010) . Testing single cells using the FISH technique has inherent technical difficulties associated with preparing a single nucleus, the stage of the mitotic cell cycle at the time of spreading, variable binding efficiency of the probes, and the arbitrary nature of scoring of FISH signals in interphase nuclei (Munné, 2002; Wilton et al., 2009; Treff et al., 2010a) . Testing is also confounded by the nature of the early embryo, where the sample may not be genetically representative of the whole embryo due to errors associated with fertilization, cell mitosis and nucleus packaging (Munné and Cohen, 1998c) . Recent studies using PCR-based PGD for Robertsonian and reciprocal translocations (Fiorentino et al., 2010; Traversa et al., 2010) offer the promise of an improved alternative to the laborious and inherently subjective FISH technique, and microarray-based comparative genomic hybridization and single nucleotide polymorphism quantitative and genotype analysis techniques have the potential for accurate testing of all 23 pairs of chromosomes (Wells et al., 2008; Gutiérrez-Mateo et al., 2010; Handyside et al., 2010; Treff et al., 2010b,c) , with the important caveat that the sample tested is truly representative of the embryo. Our study presents a comprehensive evaluation of PGD at a single centre using the FISH technique for carriers of Robertsonian translocations, which we hope will be of value in helping us to evaluate existing and new approaches to PGD.
In conclusion, our findings show that although alternate segregation is favoured for both female and male carriers of 13/14 and 14/21 Robertsonian translocations, female carriers are approximately four times more likely to produce embryos with unbalanced translocation products; this will apply regardless of which technology is used for testing. Following appropriate genetic counselling, PGD using the FISH technique should be considered as an alternative to PND for female carriers of 14/21 Robertsonian translocations to reduce the significant risk of Down syndrome and possibly miscarriage, and could be indicated to reduce the risk of miscarriage for female carriers of 13/14 Robertsonian translocations.
PGD for fertile male carriers of 13/14 and 14/21 Robertsonian translocations is unlikely to be indicated; however, revising our previous recommendation (Scriven et al., 2001) , we conclude that, where assisted conception is indicated, embryo transfer without PGD should be considered a reasonable option in the case of male carriers. We believe that couples who are unlikely to benefit from PGD (because treatment will not increase their chance of achieving a successful, chromosomally balanced pregnancy) should not undergo an expensive and invasive intervention unnecessarily.
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